Compare MEDINOVA DIA with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MEDINOVA DIAG. vs ASPIRA PATHLAB & DIAGNOSTICS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MEDINOVA DIAG. ASPIRA PATHLAB & DIAGNOSTICS MEDINOVA DIAG./
ASPIRA PATHLAB & DIAGNOSTICS
 
P/E (TTM) x 12.4 32.5 38.2% View Chart
P/BV x - 11.1 - View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 MEDINOVA DIAG.   ASPIRA PATHLAB & DIAGNOSTICS
EQUITY SHARE DATA
    MEDINOVA DIAG.
Mar-21
ASPIRA PATHLAB & DIAGNOSTICS
Mar-21
MEDINOVA DIAG./
ASPIRA PATHLAB & DIAGNOSTICS
5-Yr Chart
Click to enlarge
High Rs3137 84.7%   
Low Rs1120 57.0%   
Sales per share (Unadj.) Rs12.814.8 86.4%  
Earnings per share (Unadj.) Rs1.91.3 142.2%  
Cash flow per share (Unadj.) Rs2.62.7 95.6%  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs-7.28.1 -89.3%  
Shares outstanding (eoy) m9.9810.29 97.0%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.71.9 86.6%   
Avg P/E ratio x11.121.1 52.6%  
P/CF ratio (eoy) x8.110.3 78.3%  
Price / Book Value ratio x-2.93.5 -83.9%  
Dividend payout %00-   
Avg Mkt Cap Rs m211291 72.6%   
No. of employees `000NANA-   
Total wages/salary Rs m1740 42.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m127152 83.8%  
Other income Rs m12 66.7%   
Total revenues Rs m129154 83.6%   
Gross profit Rs m3035 85.5%  
Depreciation Rs m714 49.6%   
Interest Rs m59 51.9%   
Profit before tax Rs m2014 142.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m10-   
Profit after tax Rs m1914 137.9%  
Gross profit margin %23.623.1 102.1%  
Effective tax rate %2.90-   
Net profit margin %14.99.1 164.6%  
BALANCE SHEET DATA
Current assets Rs m1639 40.0%   
Current liabilities Rs m8020 395.4%   
Net working cap to sales %-50.212.3 -408.5%  
Current ratio x0.21.9 10.1%  
Inventory Days Days193 544.4%  
Debtors Days Days188409 46.0%  
Net fixed assets Rs m2579 32.0%   
Share capital Rs m100103 96.7%   
"Free" reserves Rs m-172-20 866.9%   
Net worth Rs m-7283 -86.6%   
Long term debt Rs m338 427.0%   
Total assets Rs m41118 34.6%  
Interest coverage x5.22.5 205.5%   
Debt to equity ratio x-0.50.1 -493.2%  
Sales to assets ratio x3.11.3 242.0%   
Return on assets %58.019.3 300.7%  
Return on equity %-26.516.6 -159.3%  
Return on capital %-61.825.0 -247.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m00-   
Fx outflow Rs m00-   
Net fx Rs m00-   
CASH FLOW
From Operations Rs m1957 34.1%  
From Investments Rs m-3-1 339.1%  
From Financial Activity Rs m-14-22 63.3%  
Net Cashflow Rs m234 7.3%  

Share Holding

Indian Promoters % 62.1 36.3 171.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.0 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 37.9 63.8 59.4%  
Shareholders   9,804 710 1,380.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MEDINOVA DIAG. With:   FORTIS HEALTHCARE  INDRAPRASTHA MEDICAL  THYROCARE TECHNOLOGIES  DR. LAL PATHLABS  METROPOLIS HEALTHCARE  



Today's Market

4 Reasons Why Sensex Surged 1,016 Points Today(Closing)

Indian share markets continued their momentum and ended their day on a strong note today.

Related Views on News

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

From Paytm to Reliance Power: Big IPOs with the Worst Debut Day Performance (Views On News)

Nov 22, 2021

Paytm's flop show should not come as a surprise. This is not the first time a high-profile IPO has eroded investors' wealth on listing day.

Top 5 Stocks in which FIIs Sequentially Raised their Stakes (Views On News)

Oct 26, 2021

FIIs have largely stayed on the sidelines this month, booking profits at every opportunity they get, amid tapering concerns.

India's New Drone Scheme: Watch Out for these Stocks (Views On News)

Oct 1, 2021

New drone rules and the PLI scheme is a huge confidence booster for startups and MSMEs. It will open new opportunities for drone companies.

Why Zomato Stopped its Grocery and Nutraceutical Businesses (Views On News)

Sep 13, 2021

Zomato believes its investment in Grofers will generate better results rather than its in-house grocery effort.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for(Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

6 Penny Stocks that Rallied 1,000%+ in One Year(Views On News)

Dec 6, 2021

These penny stocks shed their penny status by surging 1,000% or more in the last one year.

The Biggest Winners and Losers in India's Transition to Electric Vehicles(Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MEDINOVA DIAG. SHARE PRICE


Dec 8, 2021 (Close)

TRACK MEDINOVA DIAG.

  • Track your investment in MEDINOVA DIAG. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON MEDINOVA DIAG.

MEDINOVA DIAG. 5-YR ANALYSIS

COMPARE MEDINOVA DIAG. WITH

MARKET STATS